Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | MDH1 | P40925 | 1/20 | 0.36 |
| ▸ | MDH2 | P40926 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083017 | 0.79 | PPARD (0.47) | PPARDMAOBALDH1A1DRD2 | |
| SCHEMBL4212157 | 0.75 | F2 (0.38) | ALDH1A1KMT2AAR | |
| SCHEMBL227610 | 0.75 | CACNA1H (0.46) | PPARDCA1CA2CA9MAOB | |
| SCHEMBL15862911 | 0.73 | SLC6A3 (0.54) | PTGS2KMT2A | |
| SCHEMBL323068 | 0.73 | USP2 (0.42) | ALDH1A1 | |
| SCHEMBL27830058 | 0.72 | CA1 (0.40) | PPARDCA1CA2CA9MAOB | |
| SCHEMBL27905697 | 0.70 | PPARD (0.39) | PPARDMAOBALDH1A1DRD2 | |
| SCHEMBL10151717 | 0.69 | PPARD (0.45) | PPARDCA1CA2CA9MAOB | |
| SCHEMBL3515347 | 0.69 | CA1 (0.35) | CA1CA2CA9MAOBALDH1A1 | |
| SCHEMBL6937934 | 0.68 | CA1 (0.66) | CA1CA2CA9ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2012-12-20 | — | — | US | disclosed |
| US-8258177-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| CN-1882524-B | 4- ((phenoxyalkyl) thio) -phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV | 2011-06-08 | — | — | CN | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| CN-1882524-A | 4- ((phenoxyalkyl) thio) -phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1670744-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACI DS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005030694-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885CA1 4761/4885CA2 2857/4885 |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885CA1 4761/4885CA2 2857/4885 |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885CA1 4761/4885CA2 2857/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARD 3/4885CA1 4761/4885CA2 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.